跳至主要内容
临床试验/NCT01780311
NCT01780311Unknown4 期

Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias

Ospedale San Donato1 个研究点 分布在 1 个国家开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
试验地点
1
主要终点
SF-36 score

研究概览

简要总结

A randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following:
  • >2000 isolated VEB/24h
  • symptomatic monomorphic ventricular tachycardia
  • left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy

排除标准

  • known structural heart disease
  • life expectancy < 1 year

研究组 & 干预措施

Antiarrhythmic drugs

Active Comparator

Flecainide or Propafenone or Sotalol (oral, standard dosage)

干预措施: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol) (Drug)

ABLATION

Experimental

Catheter Ablation

干预措施: Catheter Ablation (Procedure)

结局指标

主要结局

SF-36 score

时间窗: 6 months

Quality of life improvement according to SF-36 score variations

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Leonardo Bolognese, MD

Director

Ospedale San Donato

研究点 (1)

Loading locations...

相似试验